Jan Geissler: Empowering Early-Career Hematologists Through EHA’s CRTH Program
Jan Geissler, Founder and CEO of Patvocates, shared a post on LinkedIn.
“Early-career hematologists designing their first clinical studies bring something unique: they are hungry for innovation, full of ideas, super motivated, energetic, and eager to challenge the status quo in treating current hematological diseases like AML, Lymphoma, CLL and Multiple Myeloma, the European Hematology Association (EHA) has run the ‘Clinical Research Training in Hematology (CRTH)’ for quite a number of years.
CRTH is a specialized training and mentoring programme designed to help young hematologists advance their career and their knowledge in clinical science.
Scholars who have successfully applied for the programme with their clinical research project concept are attending two multi-day workshops and a training session at the EHA Congress over a duration of 9 months.
A faculty of 16 experts coach and train the 20 scholars on e.g. clinical research methodology, biostatistics, diversity in trials, digital health, trial data management, trial budgeting, career development, trial design and their own draft clinical trials — all through interactive workshops, mentoring, and plenty of open discussion (sometimes even over late-night karaoke).
For the past four years, I’ve had the privilege of serving in the faculty as the only patient advocate. This week, in a farmhouse just outside Madrid, I held a training on patient engagement in clinical trials, and engagement of patient organisations in publicly funded projects. In the September session, I will train on using PROs in hematology trials and on patient literacy about research.
Programs like CRTH create an amazing space for learning and for creating a network between the scholars which will last forever. CRTH scholars of previous years are now shaping research, publishing data, and contribute to EHA’s committees, demonstrating that this programme really has impact on advancement of science, clinical practice and research collaboration.
I am grateful to the EHA team, the inspiring faculty, and the brilliant 2026 CRTH Scholars for the chance to exchange ideas, challenge perspectives, and see the rise of a new generation of hematologists.
Specific thanks to Jennifer Scheffer, Audrey Urighe, Sirpa Leppa, Urania Dafni, Verena Gaidzik, Ron van der Holt, Oscar Brück, Marije Faber, Tarec Christoffer El-Galaly, Maaike Leidekker, Marie von Lilienfeld, Mandy L., Kate Cwynarski, Christina Yap, Charles la Porte, Amy Kirkwood, Mika Kontro and Paula Rodríguez Otero, as well to the European Hematology Association of course!”
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 8, 2026, 10:29Bringing Hemophilia Care Closer to Communities in Togo – WFH
-
Jul 8, 2026, 10:12Natasha Jolakoski: Completing Advanced Training in Thrombosis and Hemostasis
-
Jul 8, 2026, 09:58Rola Ghasoub: Early Intracranial Hemorrhage Remains the Main Barrier to Cure in Acute Promyelocytic Leukemia
-
Jul 8, 2026, 05:53Excellent PhD Defense by Roberta Cirsmaru on Gene Therapy for Hemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Jul 8, 2026, 05:48Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
-
Jul 8, 2026, 05:39Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis
-
Jul 8, 2026, 04:50Reza Bavarsad Shahripour: New AHA Guidance on Cryptogenic Stroke with Reduced Left Ventricular Function
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism
-
Jul 7, 2026, 23:03Roxana González Mazarío: The Phenotype-Specific Cardiovascular Risks in AAV